Clinical impact of second pathology opinion: A longitudinal study of central genitourinary pathology review before prostate brachytherapy

Brachytherapy

Volumn 6, Issue 2, 2007, Pages 135-141

  Thomas, Carys W ^a   Bainbridge, Terry C ^a   Thomson, Thomas A ^a   McGahan, Colleen E ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brachytherapy; Pathology review; Prostate cancer

Indexed keywords

ARTICLE; BRACHYTHERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOLOGIST; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; UROGENITAL TRACT DISEASE;

BRACHYTHERAPY; BRITISH COLUMBIA; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASM STAGING; OBSERVER VARIATION; PATHOLOGY, CLINICAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RESEARCH DESIGN; RETROSPECTIVE STUDIES; UROGENITAL SYSTEM;

EID: 34047276643     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2006.10.003     Document Type: Article

References (48)

1. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
2. Gleason D.F. Histologic grading of prostate cancer: A perspective. Hum Pathol 23 (1992) 273-279
3. Sogani P.C., Israel A., Lieberman P.H., et al. Gleason grading of prostate cancer: A predictor of survival. Urology 25 (1985) 223-227
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
5. D'Amico A.V. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntingt) 15 (2001) 1049-1059 discussion 1060-1062, 1064-1065, 1069-1070, 1073-1075
6. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
7. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 79 (1997) 337-344
8. Allsbrook Jr. W.C., Mangold K.A., Johnson M.H., et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Hum Pathol 32 (2001) 81-88
9. Allsbrook Jr. W.C., Mangold K.A., Johnson M.H., et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Hum Pathol 32 (2001) 74-80
10. Oyama T., Allsbrook Jr. W.C., Kurokawa K., et al. A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States. Arch Pathol Lab Med 129 (2005) 1004-1010
11. Ozdamar S.O., Sarikaya S., Yildiz L., et al. Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas. Int Urol Nephrol 28 (1996) 73-77
12. di Loreto C., Fitzpatrick B., Underhill S., et al. Correlation between visual clues, objective architectural features, and interobserver agreement in prostate cancer. Am J Clin Pathol 96 (1991) 70-75
13. Svanholm H., and Mygind H. Prostatic carcinoma reproducibility of histologic grading. Acta Pathol Microbiol Immunol Scand [A] 93 (1985) 67-71
14. Nguyen P.L., Schultz D., Renshaw A.A., et al. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol 22 (2004) 295-299
15. Wurzer J.C., Al-Saleem T.I., Hanlon A.L., et al. Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: Correlation of pathologic findings, analysis of cost, and impact on treatment. Cancer 83 (1998) 753-759
16. Guileyardo J.M., Sarma D.P., Johnson W.D., et al. Incidental prostatic carcinoma: Tumor extent versus histologic grade. Urology 20 (1982) 40-42
17. Steinberg D.M., Sauvageot J., Piantadosi S., et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21 (1997) 566-576
18. Gleason D.F. Undergrading of prostate cancer biopsies: A paradox inherent in all biologic bivariate distributions. Urology 47 (1996) 289-291
19. Epstein J.I. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 24 (2000) 477-478
20. Carlson G.D., Calvanese C.B., Kahane H., et al. Accuracy of biopsy Gleason scores from a large uropathology laboratory: Use of a diagnostic protocol to minimize observer variability. Urology 51 (1998) 525-529
21. Egevad L. Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 57 (2001) 291-295
22. De la Taille A., Viellefond A., Berger N., et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum Pathol 34 (2003) 444-449
23. Kronz J.D., Silberman M.A., Allsbrook W.C., et al. A web-based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy: Validation of a new medical education paradigm. Cancer 89 (2000) 1818-1823
24. Kronz J.D., Silberman M.A., Allsbrook Jr. W.C., et al. Pathology residents' use of a Web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. Hum Pathol 31 (2000) 1044-1050
25. Ruijter E.T., van de Kaa C.A., Schalken J.A., et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180 (1996) 295-299
26. McGowan D.G., Bain G.O., and Hanson J. Evaluation of histological grading (Gleason) in carcinoma of the prostate: Adverse influence of highest grade. Prostate 4 (1983) 111-118
27. Aihara M., Wheeler T.M., Ohori M., et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43 (1994) 60-66 discussion 66-67
28. Pan C.C., Potter S.R., Partin A.W., et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: A proposal to modify the Gleason grading system. Am J Surg Pathol 24 (2000) 563-569
29. Epstein J.I., Allsbrook W.C., Amin M.B., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29 (2005) 1228-1242
30. Blasko J.C., Ragde H., and Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 137 (1991) 113-118
31. Caubet J.F., Tosteson T.D., Dong E.W., et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 (1997) 71-78
32. Eulau S.M., Tate D.J., Stamey T.A., et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
33. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
34. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
35. Morris W.J., Keyes M., McKenzie M., et al. The five-year relapse-free and overall survival following permanent 125 iodine prostate brachytherapy. J Radiother Oncol 80 S1 (2006) 42
36. Smith Jr. J.A. Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology (Huntingt) 10 (1996) 1319-1322 discussion 1324
37. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration. J Urol 160 (1998) 1685-1688
38. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 52 (2002) 461-468
39. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
40. 125I prostate brachytherapy. Brachytherapy 1 (2002) 131-137
41. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
42. Han B.H., Demel K.C., Wallner K., et al. Patient reported complications after prostate brachytherapy. J Urol 166 (2001) 953-957
43. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 712-719
44. Kang S.K., Chou R.H., Dodge R.K., et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys 50 (2001) 937-945
45. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
46. Merrick G.B.W., Farthing W., Dorsey A., et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int 14 (1998) 113-121
47. Sooriakumaran P., Lovell D.P., Henderson A., et al. Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer. Clin Oncol (R Coll Radiol) 17 (2005) 655-658
48. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848